Every dog has its day, and this week it was Blue Buffalo: the year's fifth-largest IPO surged over 30%. All three initial public offerings this week raised more capital than expected as Blue Buffalo priced above its range while Neos and Live Oak...read more
Neos Therapeutics, which is developing easily swallowed formulations of ADHD treatments, raised $72 million by offering 4.8 million shares (upsized from 4.0 million) at $15, the midpoint of the range of $14 to $16. Neos Therapeutics plans to list on the Nasdaq...read more
Fast-growing and highly-profitable pet food maker Blue Buffalo could be top dog this week. Five businesses and one blank check company are on the IPO calendar to raise over $1 billion. The third quarter has already seen more consumer IPOs than the first...read more
Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday.
The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 ...read more
US IPO Weekly Recap: All natural pet food maker is top dog in a week with three IPOs
Every dog has its day, and this week it was Blue Buffalo: the year's fifth-largest IPO surged over 30%. All three initial public offerings this week raised more capital than expected as Blue Buffalo priced above its range while Neos and Live Oak...read more
Neos Therapeutics prices upsized IPO at the $15 midpoint
Neos Therapeutics, which is developing easily swallowed formulations of ADHD treatments, raised $72 million by offering 4.8 million shares (upsized from 4.0 million) at $15, the midpoint of the range of $14 to $16. Neos Therapeutics plans to list on the Nasdaq...read more
Week ahead: 5 IPOs during the week of July 20 are led by a Blue Buffalo
Fast-growing and highly-profitable pet food maker Blue Buffalo could be top dog this week. Five businesses and one blank check company are on the IPO calendar to raise over $1 billion. The third quarter has already seen more consumer IPOs than the first...read more
ADHD biotech Neos Therapeutics sets terms for $60 million IPO
Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday. The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 ...read more